| 75 | 6 | 32 |
| 下载次数 | 被引频次 | 阅读次数 |
目的分析康复新液联合二线药物对老年耐多药结核病的影响。方法选取2015年1月1日-2018年12月31日在河北省胸科医院结核四科接受治疗的老年耐多药结核病患者316例,随机数字表法分成对照组(158例),采用常规二线药物治疗,观察组(158例)在对照组基础上使用康复新液治疗。对比2组患者的咯血症状变化情况、痰菌阴转情况、空洞闭合情况、临床疗效及药物不良反应发生状况。结果观察组患者在治疗3个月时咳血症状变化总有效率为100%,对照组为91.47%,差异有统计学意义(P<0.05);观察组治疗3个月、6个月末时的痰菌转阴率为89.87%和100%,高于对照组的82.91%和91.57%(P<0.05);治疗6个月后,观察组患者空洞闭合的总有效率高于对照组(P<0.05);观察组患者的临床总有效率高于对照组(P<0.05);观察组患者出现不良反应例数合计26例,占比16.46%,对照组出现不良反应例数合计30例,占比18.99%,治疗前后2组无明显差异(P>0.05),但观察组胃肠道反应发生率明显低于对照组。结论康复新液联合二线药物可有效治疗老年耐多药结核病,显著提高患者的痰菌阴转率,有效控制咳血,促进空洞闭合,降低患者胃肠道反应发生率,临床效果较好。
Abstract:Objective To analyze the effect of Kangfuxin fluid combined with the second-line drugs on the elderly with multidrug-resistant tuberculosis(MDR-TB). Methods From January 1 st 2015 to December 31 st 2018, a total of 316 elder MDR-TB patients who were treated in four departments of tuberculosis of Hebei Chest Hospital were randomly divided into control group(158 cases) and observation group(158 cases) respectively. The changes of hemoptysis symptoms, sputum negative transformation, cavity closure, clinical efficacy and adverse drug reactions were compared between the two groups. Results The total effective rate of hemoptysis was 100% in the observation group and 91.47% in the control group(P<0.05). At the end of 3 and 6 months. The negative conversion rate of sputum bacteria was 89.87% and 100%, which were higher than that in the control group(P<0.05). After 6 months of treatment, the total effective rate of cavity closure in the observation group was higher than that of the control group(P<0.05). The clinical efficacy of the observation group was higher than that of the control group(P<0.05). A total of 26 cases(16.46%) were found in the observation group and 30 cases(18.99%) in the control group. There was no significant difference between the two groups(P>0.05), but the incidence of gastrointestinal reaction in the observation group was significantly lower than that in the control group. Conclusion Kangfuxin fluid combined with the second-line drugs can effectively treat multidrug-resistant tuberculosis in the elderly, significantly improve the rate of sputum turnover, effectively control hemoptysis, promote cavity closure, reduce the incidence of gastrointestinal reactions in patients, and have a good clinical effect.
[1] 陆震宇,杨明芳,陈纬.结核病实验室诊断技术评价及其研究进展[J].中国卫生检验杂志,2017(2):301-304.
[2] 龚清河.上海市崇明区2016至2017年活动性肺结核流行病学分析[J].中国临床医学,2018,25(6):164-166.
[3] 庞学文,李晓蓉,李敬新.2009-2017年天津市老年肺结核流行特征分析[J].中国慢性病预防与控制,2018,26(9):20-23.
[4] 王晓宁,何天伦,耿梦杰,等.我国12省结核病门诊和实验室感染控制管理措施实施现状的抽样调查及其主成分分析[J].中国防痨杂志,2018,40(5):519-524.
[5] SAID K,HELLA J,MHALU G,et al.Diagnostic delay and associated factors among patients with pulmonary tuberculosis in Dar es Salaam,Tanzania:[J].Infect Dis Poverty,2017,6(1):64-68.
[6] 桑文涛,余芳蓉,杨泽越,等.康复新液防治口腔疾病的研究进展[J].世界中医药,2019,14(1):270-275.
[7] 成诗明.我国耐多药结核病防治现状与建议[J].中国热带医学,2017,17(3):213-215.
[8] 李慧,田芝奥,吴霞.648例结核病患者抗结核药物所致不良反应及危险因素分析[J].中国防痨杂志,2017,39(11):1241-1246.
[9] 谢婷婷,郭代红,赵粟裕,等.军队医院1298例质子泵抑制剂类药物药品不良反应分析[J].药学服务与研究,2018,18(3):19-22.
[10] 翁涵,金海,庹必光.质子泵抑制剂抗肿瘤机制的研究进展[J].医学综述,2017,23(3):465-469.
[11] 周海辉,张海霞,葛卫红.质子泵抑制剂和化疗药物的协同效应[J].药学与临床研究,2018,26(5):49-51.
[12] 卢宏丽,卢宏霞.山西省某肿瘤医院住院患者质子泵抑制剂用药分析[J].中国药物与临床,2017,17(6):905-906.
[13] 肖智,陈亮,刘洋.不同质子泵抑制剂三联疗法治疗幽门螺杆菌相关性消化性溃疡的疗效比较[J].医学综述,2017,23(5):1026-1029.
[14] 王红,郑金萍.康复新液辅助治疗肺结核合并糖尿病的疗效及对糖化血红蛋白与T淋巴细胞亚群的影响[J].现代中西医结合杂志,2017,13(24):29-31.
[15] PANDA A,BHALLA A S,GOYAL A.Bronchial artery embolization in hemoptysis:a systematic review[J].Diag Intervent Radiol,2017,23(4):307-317.
[16] 吕娜,沈连刚,李广志,等.康复新液化学成分研究[J].中国现代中药,2017,19(4):488-490.
[17] 胡彩霞,张国强,崔瑜,等.康复新液联合强脉冲光治疗玫瑰痤疮的临床观察[J].中国药房,2017,28(17):2399-2402.
[18] 王姬,谢固雅,冯马龙.康复新液联合标准化疗方案治疗空洞型肺结核并发咯血93例[J].医药导报,2018,37(4):1-2.
[19] 郑雅楠,张晨,辛秀梅,等.不同发现方式在结核病发现中的作用[J].新疆医科大学学报,2015,38(6):772-773.
[20] 陈红梅,赵海波.康复新液联合重组人酸性成纤维细胞生长因子对湿热下注型肛瘘术后创面愈合的影响[J].现代中西医结合杂志,2017,26(13):1420-1422.
基本信息:
中图分类号:R52
引用信息:
[1]康冠楠,侯莉莉,马清艳,等.康复新液联合二线药物对老年耐多药结核病患者影响的临床研究[J].新疆医科大学学报,2020,43(06):754-757+762.
基金信息:
河北省医学科学研究计划项目(20191033)
2020-06-15
2020-06-15